Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 12,225 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Diseases Clear all

Conditions: Developmental Disability, Autism Spectrum Disorder, Down Syndrome, Cerebral Palsy
Interventions: Zumba High Tempo, Zumba Low Tempo; Behavioral
Lead sponsor: Auburn University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Obesity, Hepatic Insufficiency
Interventions: CP-945,598; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Rheumatoid Arthritis (RA)
Interventions: abatacept, Methotrexate (MTX); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 15
States / cities: Huntsville, Alabama • Mobile, Alabama • Palo Alto, California + 12 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS, Physical Examination; Other
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: ADHD
Interventions: SPD503-AM, SPD503-PM, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 61
States / cities: Dothan, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 53 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Targeted Ballet Program; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Champaign, Illinois

Conditions: Short Bowel Syndrome
Interventions: Not listed
Lead sponsor: Shire; Industry
Eligibility: Not listed
Enrollment: 1,806 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2032
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Obesity, Pregnancy Related
Interventions: HABITpreg, HABITpost; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 14 Years and older · Female only
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Laryngopharyngeal Reflux
Interventions: Reza Band UES Assist Device; Device
Lead sponsor: Somna Therapeutics, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 5
States / cities: New York, New York • Nashville, Tennessee • Milwaukee, Wisconsin + 1 more

Conditions: Non-small Cell Lung Cancer
Interventions: Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib; Drug · Procedure
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 38
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 28 more

Conditions: Tinea Pedis, Athlete's Foot
Interventions: Econazole Nitrate Foam 1%, Vehicle Foam; Drug · Other
Lead sponsor: AmDerma; Industry
Eligibility: 12 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Miramar, Florida • Clinton Township, Michigan • Las Vegas, Nevada + 4 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: mRNA-2736; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 11
States / cities: Birmingham, Alabama • Miami, Florida • St Louis, Missouri + 7 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg); Drug
Lead sponsor: PhenoNet, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more

Conditions: Acute Respiratory Distress Syndrome
Interventions: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells; Biological
Lead sponsor: Michael A. Matthay; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: San Francisco, California • Stanford, California • Boston, Massachusetts + 1 more

Conditions: Sickle Cell Anemia
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 8 Years to 20 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Atlanta, Georgia • Augusta, Georgia • Greenville, North Carolina

Conditions: Multiple Sclerosis, Relapse
Interventions: Blood samples and processing; Diagnostic Test
Lead sponsor: Regina Elena Cancer Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Disease of Cardiovascular System, Multiple Chronic Conditions, Chronic Disease
Interventions: MOCHA; Behavioral
Lead sponsor: University of Massachusetts, Amherst; Other
Eligibility: 35 Years to 70 Years · Male only
Enrollment: 261 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Amherst, Massachusetts • Springfield, Massachusetts

Conditions: Renal Dialysis
Interventions: BAY1213790, 0.9% sodium chloride solution; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Chula Vista, California • Bradenton, Florida • Chicago, Illinois + 1 more

Conditions: Obesity and Overweight
Interventions: MET097, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Scottsdale, Arizona • Canoga Park, California • Oxnard, California + 33 more

Conditions: Neoplasms, Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions: TPI 287 Injection; Drug
Lead sponsor: Cortice Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 4
States / cities: Tucson, Arizona • Denver, Colorado • Washington D.C., District of Columbia + 1 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: PR610; Drug
Lead sponsor: Proacta, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Scottsdale, Arizona • Sacramento, California • Chicago, Illinois + 1 more

Conditions: Opioid-Induced Bowel Dysfunction
Interventions: Lubiprostone 24; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 120
States / cities: Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 95 more

Conditions: MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions: Resmetirom; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Spasticity, Multiple Sclerosis
Interventions: IPX056, Baclofen IR, Placebo IPX056, Placebo IR; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Tucson, Arizona • Aurora, Colorado • Tampa, Florida + 8 more

Search by objective public record fields.

The Effects of Virtual Zumba® in Individuals With Developmental Disabilities

Study Examining The Effect Of Hepatic Impairment On Safety, Toleration And How The Body Processes An Experimental Drug

Phase IIIB Subcutaneous Abatacept Monotherapy Study

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

Efficacy and Safety of SPD503 in Combination With Psychostimulants

Exploration of Brain Changes Due to a Targeted Ballet Program in Multiple Sclerosis

Registry for Participants With Short Bowel Syndrome

Optimizing Health From Pregnancy Through One Year Postpartum

Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis

mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis

MOCHA Moving Forward: a CBPR Investigation of Chronic Disease Prevention in Older, Low-income African-American Men

End-stage Renal Disease (ESRD) Pilot Study

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Study of TPI 287 in Patients With Advanced Malignancies

A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone

Study of Resmetirom in Children and Adolescents With MASH

A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis